KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4), also known as MinK-related peptide 4 (MiRP4), is a critical regulatory subunit that modulates the function of various voltage-gated potassium (Kv) channels. KCNE proteins are a family of small single-pass membrane proteins that associate with Kv channel alpha subunits to form functional channel complexes with distinct biophysical properties. KCNE4, the least characterized member of the KCNE family, is expressed in both cardiac and neuronal tissues where it plays crucial roles in regulating excitability and cellular function[1].
In the nervous system, KCNE4-containing channels contribute to neuronal repolarization, neurotransmitter release, and synaptic plasticity. Emerging evidence suggests that KCNE4 dysfunction may contribute to neurodegenerative processes in Alzheimer's disease, Parkinson's disease, and other neurological disorders. The protein's dual expression in brain and heart also raises important considerations for therapeutic targeting, as modulators affecting KCNE4 function may have both neurological and cardiac effects[2].
The KCNE4 gene is located on chromosome 2q36.1 in humans, spanning approximately 6.5 kb of genomic DNA. The gene consists of 3 exons encoding a protein of 180 amino acids with a molecular weight of approximately 21 kDa. The gene is subject to alternative splicing, generating multiple transcript variants with tissue-specific expression patterns.
| Property | Value |
|---|---|
| Gene Symbol | KCNE4 |
| Alternative Names | MiRP4, EPLG4 |
| Chromosomal Location | 2q36.1 |
| NCBI Gene ID | 23704 |
| OMIM | 607334 |
| UniProt ID | Q9P110 |
| Protein Length | 180 amino acids |
KCNE4 shares the characteristic structure of KCNE family proteins:
The cytoplasmic domain contains multiple phosphorylation sites and protein-protein interaction motifs that enable KCNE4 to modulate channel gating and trafficking.
KCNE4 associates with multiple Kv channel alpha subunits to form heteromeric channels with unique properties:
Main Channel Partners:
Functional Effects:
KCNE4 binding typically produces:
In neurons, KCNE4-containing channels contribute to:
Membrane Repolarization: Following action potential generation, KCNE4 channels contribute to rapid repolarization, enabling high-frequency firing in fast-spiking neurons.
Resting Membrane Potential: KCNQ2/3 channels regulated by KCNE4 set the resting membrane potential and control neuronal input resistance.
Neurotransmitter Release: Presynaptic Kv channels influence calcium influx during action potentials, modulating neurotransmitter release probability.
Synaptic Integration: Dendritic Kv channels affect synaptic integration and temporal processing of incoming signals[3].
KCNE4 dysfunction is implicated in Alzheimer's disease (AD) through multiple mechanisms:
Amyloid-beta interaction: Aβ oligomers directly affect KCNE4 channel function. Studies show that Aβ exposure:
Channel dysfunction: Post-mortem studies of AD brains reveal altered KCNE4 expression in the hippocampus and cortex, regions critical for memory formation[4]. The changes in KCNE4 expression correlate with:
Therapeutic implications: KCNE4 and associated KCNQ channels represent promising targets for AD therapy. Current approaches include:
KCNE4 involvement in Parkinson's disease (PD) is an emerging area of research:
Dopaminergic neuron function: KCNE4 is expressed in dopaminergic neurons of the substantia nigra pars compacta, where it modulates Kv channel function. Changes in KCNE4 may contribute to:
Neuroinflammation: KCNE4 is expressed in microglia, where Kv channels regulate microglial activation and neuroinflammatory responses[5]. Altered KCNE4 function may contribute to chronic neuroinflammation in PD.
Epilepsy: KCNE4 variants have been associated with epilepsy susceptibility. KCNE4 modulates neuronal excitability, and dysfunction may contribute to seizure generation.
Stroke and excitotoxicity: Following ischemic injury, KCNE4 expression and function are altered, affecting neuronal survival and recovery[6].
Neuropathic pain: KCNE4 in sensory neurons contributes to pain signaling, and altered expression is observed in models of neuropathic pain.
KCNE4 exhibits region-specific and cell-type-specific expression in the central nervous system:
| Region | Expression Level | Primary Cell Types |
|---|---|---|
| Hippocampus (CA1, CA3) | High | Pyramidal neurons, interneurons |
| Cortex (layers II-VI) | Moderate-High | Pyramidal neurons, interneurons |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Thalamus | Moderate | Thalamic relay neurons |
| Basal ganglia | Moderate | Medium spiny neurons |
| Substantia nigra | Moderate | Dopaminergic neurons |
| Brainstem | Low-Moderate | Various neuron types |
KCNE4 expression changes during development:
| Channel | Subunit | Functional Effect |
|---|---|---|
| KCNQ2/KCNQ3 | Kv7.2/7.3 | M-current modulation |
| KCNQ1 | Kv7.1 | Cardiac/brain expression |
| Kv1.1 | KCNA1 | Delayed rectifier modulation |
| Kv1.2 | KCNA2 | Fast transient currents |
| Kv3.1 | KCNC1 | Fast-spiking neuron modulation |
KCNE4 is regulated by multiple signaling mechanisms:
KCNE4 and its partner channels represent attractive therapeutic targets:
KCNQ2/3 Activators:
Considerations:
KCNE4 expression in peripheral tissues may serve as a biomarker for neuronal Kv channel function:
| Disease | Association | Evidence |
|---|---|---|
| Alzheimer's Disease | Risk factor/modifier | Expression studies, functional assays |
| Parkinson's Disease | Potential modifier | Expression data, model systems |
| Epilepsy | Risk factor | Genetic association studies |
| Atrial Fibrillation | Risk factor | KCNE4 deletion variant association |
| Long QT Syndrome | Modifier | Cardiac phenotype modulation |
Several KCNE4 variants have been identified:
KCNE4 is a critical regulatory subunit of voltage-gated potassium channels with important roles in neuronal excitability, synaptic function, and cellular homeostasis. Its expression in both the brain and heart, combined with emerging evidence of dysfunction in Alzheimer's disease and Parkinson's disease, makes KCNE4 an important protein in neurodegenerative research. Understanding KCNE4's precise functions and developing targeted therapeutic approaches may provide new strategies for treating these devastating disorders.
Abbott GW. KCNE4 and KCNE5: subunits that shape excitability in health and disease. Journal of Molecular and Cellular Cardiology. 2018. ↩︎
Shah NH, et al. Neuronal potassium channels: emerging therapeutic targets for neurodegeneration. Cell Calcium. 2018. ↩︎
Kawasaki H, et al. Expression and localization of KCNE4 in the rodent brain. Journal of Comparative Neurology. 2019. ↩︎
Yang Y, et al. Potassium channel dysfunction in Alzheimer's disease: evidence and mechanisms. Neurobiology of Aging. 2019. ↩︎
Liu Y, et al. Potassium channels in microglia and their role in neuroinflammation. Glia. 2017. ↩︎
Mendelsohn AD, et al. Targeting potassium channels for neuroprotection in stroke. Brain Research. 2019. ↩︎